ALung Technologies
ALung Technologies develops medical gas exchange devices for acute and chronic respiratory disorders using proprietary perfusion technology, serving pediatric healthcare institutions. Founded in 1997 in Pittsburgh, it competes alongside Medtronic, LivaNova, and Edwards Lifesciences in the cardiopulmonary device market.
- Company typePublic
- Founded2015
- HeadquartersPittsburgh, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ALung Technologies does
ALung Technologies is a private, for-profit medical device company founded in 1997 and headquartered in Pittsburgh, Pennsylvania. The company develops medical gas exchange devices intended for the treatment of acute and chronic respiratory disorders, built around proprietary perfusion technology for cardiopulmonary applications. The input identifies a proprietary "Continuous Perfusion Sensing Technology" tied to novel method/architecture innovation in pediatric perfusion device design, positioning ALung as a participant — alongside Medtronic, LivaNova, and Edwards Lifesciences — in the broader cardiopulmonary medical device landscape, with a stated emphasis on the pediatric perfusion subsegment.
The company's go-to-market orientation is B2B, targeting healthcare institutions and providers specializing in pediatric cardiac and perfusion care. Pricing and revenue model details are not publicly disclosed in the available sources, and no named end-customer logos are present in the input. The company has maintained a small operating footprint of 11–50 employees, with leadership weighted toward regulatory, quality, and scientific affairs expertise — consistent with a company focused on regulated medical device development and clinical pathway execution rather than scaled commercial deployment.
ALung has financed its development through approximately $112.9M in disclosed funding across eleven rounds from 2009 through November 2020, with the 2017 round ($36M, co-led by Philips Healthcare and UPMC) representing the company's most significant capital event and the closest indication of strategic OEM validation. Cumulative funding, headcount scale, and the absence of disclosed revenue or post-2020 capital activity indicate a company that has not yet reached scaled commercialization as represented in the input data.
ALung Technologies firmographics
Firmographics- Name
- ALung Technologies
- Legal name
- LivaNova PLC
- Website
- https://alung.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ALung Technologies develops medical gas exchange devices for acute and chronic respiratory disorders using proprietary perfusion technology, serving pediatric healthcare institutions. Founded in 1997 in Pittsburgh, it competes alongside Medtronic, LivaNova, and Edwards Lifesciences in the cardiopulmonary device market.
- Ownership category
- akta.pro rank
ALung Technologies industry classification
Industry- Product category
- Respiratory Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home) (HLAHAGAC)
- akta.pro secondary industry
- Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers) (HLAHAGAK)
Keywords
Where ALung Technologies is headquartered
LocationHeadquarters
- HQ city
- Pittsburgh
- HQ country
- United States
- HQ region
- North America
Markets served
ALung Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
ALung Technologies product offering
Product offeringCore offering
ALung Technologies develops medical gas exchange devices used in the treatment of acute and chronic respiratory disorders. The company's core work centers on perfusion-based cardiopulmonary medical devices, including advanced continuous perfusion sensing technology, targeted at hospitals and clinicians managing severe respiratory failure.
Differentiator
Problem solved
Functional benefit
Brands
- VNS Therapy: Vagus Nerve Stimulation therapy for epilepsy and depression treatment
- Essenz Perfusion System
- Sentiva
- Symmetry
Products and services
- Medical Gas Exchange Devices Medical devices designed to perform extracorporeal gas exchange for patients with acute and chronic respiratory disorders, used by hospitals and clinicians managing severe respiratory failure.
Companies that use ALung Technologies
Customer profileSegments1 record
Ideal customer profiles1 record
ALung Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
ALung Technologies partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights3 records
ALung Technologies competitors and assessment
Company assessmentDirect peers
- LivaNova PLC: LivaNova is a global medical device company with a dedicated cardiopulmonary business (Essenz Perfusion System) that directly competes with ALung in perfusion and extracorporeal gas exchange devices used in cardiac surgery and respiratory support. ALung's own profile lists LivaNova as a fellow leader in the pediatric perfusion market.
- Abiomed: Abiomed (a Johnson & Johnson MedTech company) develops percutaneous and extracorporeal circulatory support devices such as Impella and Breethe. It is a strategic investor in ALung and competes in the broader cardiopulmonary and mechanical circulatory support space relevant to ALung's gas exchange technology.
- Terumo Cardiovascular: Terumo Cardiovascular manufactures perfusion systems, oxygenators, and related cardiopulmonary products used in cardiac surgery. It is one of the closest direct competitors to ALung in extracorporeal gas exchange and perfusion hardware.
- Xenios AG (Fresenius Medical Care): Xenios AG, part of Fresenius Medical Care, develops ECMO and ECCO2R systems (e.g., i-cor, Hilite) used for extracorporeal lung and cardiac support. It competes with ALung's Hemolung-style gas exchange technology in respiratory and cardiac failure indications.
Broad incumbents
- Medtronic: Medtronic is one of the world's largest medical device companies with a significant perfusion and cardiopulmonary portfolio (including its legacy Covidien perfusion business). It is named alongside ALung as a leader in the pediatric perfusion market and competes across perfusion, oxygenation, and related cardiopulmonary support.
- Edwards Lifesciences: Edwards Lifesciences is a major cardiac and critical care medtech player with established products in hemodynamic monitoring and perfusion-adjacent technologies. It is named alongside ALung as a leader in the pediatric perfusion market and overlaps in cardiopulmonary support for cardiac surgery.
- Getinge (Maquet): Getinge, through its Maquet brand, is a global leader in cardiopulmonary products including heart-lung machines, oxygenators, and ECMO systems. It directly overlaps with ALung in extracorporeal gas exchange and perfusion technology for cardiac surgery and ICU respiratory support.
Regional players
- Nipro Medical Corporation: Nipro manufactures oxygenators, perfusion circuits, and dialysis-related equipment. While strongest in Japan and parts of Asia, it competes globally with ALung in cardiopulmonary disposables and extracorporeal support products.
Emerging players
- Inspira Technologies: Inspira Technologies is an emerging medical device company developing extracorporeal blood oxygenation and respiratory support systems. Its technology focus on direct blood oxygenation overlaps with ALung's gas exchange platform, making it a relevant emerging competitor.
- CytoSorbents Corporation: CytoSorbents develops extracorporeal blood purification technologies used in critical care, including for patients with respiratory failure. Its technology and clinical positioning in ICU blood/气体 exchange adjacencies make it a relevant emerging peer to ALung's extracorporeal platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
ALung Technologies social profiles
Digital presenceALung Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
ALung Technologies leadership team
Management profileNumber of profiles
Profiles7 records
ALung Technologies funding detail
Funding detailFunding overview
Funding rounds11 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ALung Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ALung Technologies
What does ALung Technologies do?
ALung Technologies develops medical gas exchange devices used in the treatment of acute and chronic respiratory disorders. The company's core work centers on perfusion-based cardiopulmonary medical devices, including advanced continuous perfusion sensing technology, targeted at hospitals and clinicians managing severe respiratory failure.
Is ALung Technologies a public or private company?
ALung Technologies is a public company. It is classified as venture growth investor backed and is currently operating.
When was ALung Technologies founded?
ALung Technologies was founded in 2015. It employs 11 to 50 people.
Where is ALung Technologies based?
ALung Technologies is headquartered in Pittsburgh, United States, in the North America region.
Who are ALung Technologies's main competitors?
Direct peers on record are LivaNova PLC, Abiomed, Terumo Cardiovascular and Xenios AG (Fresenius Medical Care). Broad incumbents are Medtronic, Edwards Lifesciences and Getinge (Maquet). Nipro Medical Corporation is listed as a regional player. Emerging players are Inspira Technologies and CytoSorbents Corporation.
Does ALung Technologies have an API?
No public API is recorded for ALung Technologies.
What industry is ALung Technologies in?
ALung Technologies's product category is Respiratory Medical Devices. Its primary akta.pro industry code is HLAHAGAC, Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home), with a secondary code of HLAHAGAK, Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers). Its NAICS code is 3391 and its SIC code is 3841.